Caribou Biosciences Stock Current Liabilities

CRBU Stock

USD 0.95 0.07 6.86%

Caribou Biosciences fundamentals help investors to digest information that contributes to Caribou Biosciences' financial success or failures. It also enables traders to predict the movement of Caribou Stock. The fundamental analysis module provides a way to measure Caribou Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Caribou Biosciences stock.

Short Long Term Debt Total Total Assets

Non Current Liabilities Total is likely to gain to about 30.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 24.8 M in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Caribou Biosciences Company Current Liabilities Analysis

Caribou Biosciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Caribou Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Caribou Biosciences is extremely important. It helps to project a fair market value of Caribou Stock properly, considering its historical fundamentals such as Current Liabilities. Since Caribou Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Caribou Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Caribou Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt	Capital Surpluse	Deferred Long Term Liab
Total Assets		1.0	0.97	0.85	-0.3	-0.77	0.15	0.29	0.95	0.67	1.0	0.81	0.99	0.94	0.99	0.63	0.94	0.76	-0.36	0.5	-0.36
Total Stockholder Equity	1.0		0.98	0.84	-0.32	-0.76	0.18	0.3	0.94	0.65	1.0	0.8	0.99	0.93	0.99	0.64	0.93	0.75	-0.35	0.49	-0.35
Net Tangible Assets	0.97	0.98		0.84	-0.31	-0.77	0.16	0.25	0.92	0.6	0.98	0.84	0.96	0.95	0.95	0.64	0.95	0.8	-0.35	0.58	-0.35
Current Deferred Revenue	0.85	0.84	0.84		-0.43	-0.51	-0.09	0.5	0.69	0.67	0.84	0.65	0.84	0.69	0.83	0.7	0.69	0.55	-0.23	0.28	-0.23
Net Debt	-0.3	-0.32	-0.31	-0.43		-0.28	-0.69	-0.89	0.0	0.33	-0.32	-0.05	-0.41	-0.04	-0.43	-0.88	-0.04	0.26	-0.36	0.39	-0.36
Retained Earnings	-0.77	-0.76	-0.77	-0.51	-0.28		0.14	0.26	-0.86	-0.72	-0.76	-0.79	-0.7	-0.91	-0.69	-0.18	-0.91	-0.83	0.78	-0.9	0.78
Accounts Payable	0.15	0.18	0.16	-0.09	-0.69	0.14		0.53	0.01	-0.56	0.18	0.05	0.27	0.06	0.29	0.6	0.06	-0.26	0.21	-0.2	0.21
Net Receivables	0.29	0.3	0.25	0.5	-0.89	0.26	0.53		0.01	-0.09	0.3	0.17	0.39	0.0	0.41	0.83	0.0	-0.31	0.32	-0.47	0.32
Short Term Investments	0.95	0.94	0.92	0.69	0.0	-0.86	0.01	0.01		0.75	0.94	0.81	0.9	0.97	0.89	0.35	0.97	0.9	-0.4	0.6	-0.4
Total Liab	0.67	0.65	0.6	0.67	0.33	-0.72	-0.56	-0.09	0.75		0.65	0.68	0.58	0.68	0.56	0.03	0.68	0.73	-0.46	0.49	-0.46
Net Invested Capital	1.0	1.0	0.98	0.84	-0.32	-0.76	0.18	0.3	0.94	0.65		0.8	0.99	0.93	0.99	0.64	0.93	0.75	-0.35	0.49	-0.35
Short Long Term Debt	0.81	0.8	0.84	0.65	-0.05	-0.79	0.05	0.17	0.81	0.68	0.8		0.76	0.87	0.74	0.44	0.87	0.75	-0.39	0.64	-0.39
Total Current Assets	0.99	0.99	0.96	0.84	-0.41	-0.7	0.27	0.39	0.9	0.58	0.99	0.76		0.9	1.0	0.71	0.9	0.68	-0.32	0.42	-0.32
Capital Stock	0.94	0.93	0.95	0.69	-0.04	-0.91	0.06	0.0	0.97	0.68	0.93	0.87	0.9		0.88	0.43	1.0	0.9	-0.49	0.74	-0.49
Net Working Capital	0.99	0.99	0.95	0.83	-0.43	-0.69	0.29	0.41	0.89	0.56	0.99	0.74	1.0	0.88		0.72	0.88	0.66	-0.3	0.4	-0.3
Short Term Debt	0.63	0.64	0.64	0.7	-0.88	-0.18	0.6	0.83	0.35	0.03	0.64	0.44	0.71	0.43	0.72		0.43	0.06	-0.06	0.03	-0.06
Common Stock	0.94	0.93	0.95	0.69	-0.04	-0.91	0.06	0.0	0.97	0.68	0.93	0.87	0.9	1.0	0.88	0.43		0.9	-0.49	0.74	-0.49
Property Plant Equipment	0.76	0.75	0.8	0.55	0.26	-0.83	-0.26	-0.31	0.9	0.73	0.75	0.75	0.68	0.9	0.66	0.06	0.9		-0.35	0.71	-0.35
Long Term Debt	-0.36	-0.35	-0.35	-0.23	-0.36	0.78	0.21	0.32	-0.4	-0.46	-0.35	-0.39	-0.32	-0.49	-0.3	-0.06	-0.49	-0.35		-0.82	1.0
Capital Surpluse	0.5	0.49	0.58	0.28	0.39	-0.9	-0.2	-0.47	0.6	0.49	0.49	0.64	0.42	0.74	0.4	0.03	0.74	0.71	-0.82		-0.82
Deferred Long Term Liab	-0.36	-0.35	-0.35	-0.23	-0.36	0.78	0.21	0.32	-0.4	-0.46	-0.35	-0.39	-0.32	-0.49	-0.3	-0.06	-0.49	-0.35	1.0	-0.82

Click cells to compare fundamentals

Caribou Current Liabilities Historical Pattern

Today, most investors in Caribou Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Caribou Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Caribou Biosciences current liabilities as a starting point in their analysis.

Caribou Biosciences Current Liabilities

Timeline

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Competition

Predict Caribou Biosciences

Total Current Liabilities Over Time

Caribou Total Current Liabilities

Total Current Liabilities

24.82 Million

At this time, Caribou Biosciences' Total Current Liabilities is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Caribou Biosciences has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.

Caribou Current Liabilities Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Caribou Biosciences' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Caribou Biosciences could also be used in its relative valuation, which is a method of valuing Caribou Biosciences by comparing valuation metrics of similar companies.

Caribou Biosciences is currently under evaluation in current liabilities category among its peers.

Caribou Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Caribou Biosciences from analyzing Caribou Biosciences' financial statements. These drivers represent accounts that assess Caribou Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Caribou Biosciences' important valuation drivers and their relationship over time.

		2020	2021	2022	2023	2024	2025 (projected)
Enterprise Value		964.3M	669.2M	351.2M	398.9M	153.8M	146.1M

Caribou Fundamentals

	Return On Equity	-0.48
	Return On Asset	-0.27
	Operating Margin	(18.43) %
	Current Valuation	(94.67 M)
	Shares Outstanding	93 M
	Shares Owned By Insiders	10.08 %
	Shares Owned By Institutions	61.64 %
	Number Of Shares Shorted	8.91 M
	Price To Book	0.35 X
	Price To Sales	8.84 X
	Revenue	9.99 M
	Gross Profit	(119.56 M)
	EBITDA	(166.62 M)
	Net Income	(149.1 M)
	Cash And Equivalents	339.92 M
	Cash Per Share	5.59 X
	Total Debt	26.49 M
	Debt To Equity	0.08 %
	Current Ratio	12.23 X
	Book Value Per Share	2.74 X
	Cash Flow From Operations	(138.2 M)
	Short Ratio	7.92 X
	Earnings Per Share	(1.65) X
	Price To Earnings To Growth	0.50 X
	Target Price	12.88
	Number Of Employees	147
	Beta	2.34
	Market Capitalization	88.38 M
	Total Asset	313.31 M
	Retained Earnings	(448.39 M)
	Working Capital	188.73 M
	Net Asset	313.31 M

About Caribou Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Caribou Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Caribou Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Caribou Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC